Navigation Links
Imaging agents offer new view of inflammation, cancer
Date:10/7/2011

A series of novel imaging agents could make it possible to "see" tumors in their earliest stages, before they turn deadly.

The compounds, derived from inhibitors of the enzyme cyclooxygenase-2 (COX-2) and detectable by positron emission tomography (PET) imaging, may have broad applications for cancer detection, diagnosis and treatment.

Vanderbilt University investigators describe the new imaging agents in a paper featured on the cover of the October issue of Cancer Prevention Research.

"This is the first COX-2-targeted PET imaging agent validated for use in animal models of inflammation and cancer," said Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology and leader of the team that developed the compounds.

COX-2 is an attractive target for molecular imaging. It's not found in most normal tissues, and then it is "turned on" in inflammatory lesions and tumors, Marnett explained.

"As a tumor grows and becomes increasingly malignant, COX-2 levels go up," Marnett said.

To develop compounds that target COX-2 and can be detected by PET imaging, Jashim Uddin, Ph.D., research assistant professor of Biochemistry, started with the "core" chemical structures of the anti-inflammatory medicines indomethacin and celecoxib and modified them to add the element fluorine in various chemical configurations.

After demonstrating that the fluorinated compounds were selective inhibitors of COX-2, the investigators incorporated radioactive fluorine (18-F) into the most promising compound. Intravenous injection of this 18-F compound into animal models provided sufficient signal for PET imaging.

The researchers demonstrated the potential of this 18-F compound for in vivo PET imaging in two animal models: irritant-induced inflammation in the rat footpad and human tumors grafted into mice.

They showed that the 18-F compound accumulated in the inflamed foot, but not the non-inflamed foot, and that pre-treatment of the animals with celecoxib blocked the signal. In mice bearing both COX-2-positive and COX-2-negative human tumors, the 18-F compound accumulated only in the COX-2-positive tumor.

The studies support further development of these agents as probes for early detection of cancer and for evaluation of the COX-2 status of pre-malignant and malignant tumors.

"Because COX-2 levels increase during cancer progression in virtually all solid tumors, we think these imaging tools will have many, many different applications," Marnett said.


'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. New research shows PET imaging effective in predicting lung cancer outcomes
2. Researchers transform iPhone into high-quality medical imaging device
3. Consider the breast and lungs when determining thoracic imaging protocols
4. Stanford brain imaging study shows physiological basis of dyslexia
5. New diagnostic imaging for lung cancer could prevent unnecessary surgery
6. Error rate higher in breast imaging reports generated by automatic speech recognition
7. Experts offer solutions at ACR Imaging Informatics Summit & Radiation Dose Monitoring Forum
8. New imaging technique visualizes cancer during surgery
9. Researchers utilize neuroimaging to show how brain uses objects to recognize scenes
10. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
11. New imaging test gives physicians better tool to diagnose Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... DC (PRWEB) , ... June 28, 2017 , ... Anyone with a remote control has ... anyone can do it, you the flipper will get rich in no time. But ... how wrong things can get for the buyer of a flipped house. An email ...
(Date:6/28/2017)... ... June 28, 2017 , ... David B. Sosin, a founding partner at ... over the post of 2nd Vice President for the Illinois State Bar Association , ... the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in that ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... American Farmer ... upcoming episode of the award winning television series, scheduled to broadcast fourth quarter 2017. ... Seeds originated as a regional supplier of garden pea seed. As demand grew, the ...
(Date:6/28/2017)... ... 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) (TSX.V: ... study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium and ... groundwater. As a part of the study, batch adsorption experiments were conducted with ...
(Date:6/28/2017)... ... 2017 , ... Doner Financial, a Cincinnati area firm that ... and financial planning services, is announcing the commencement of a local charity event ... financial crisis. , Matthew 25: Ministries (M25M) is an international organization dedicated to ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
(Date:6/8/2017)...  Less than a month ago, amateur hackers executed ... including hospital networks, in over 150 countries. ... largest online extortion attempts ever recorded. With the increasing ... imperative that providers understand where the risks lie, and ... and many other very real cyber threats.  ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
Breaking Medicine Technology: